PDCD1 and cancer: Recently, immune checkpoint inhibitors (ICIs), such as anti-programmed cell death-1 (PD-1) or programmed cell death ligand-1 (PD-L1) monoclonal antibodies, have improved the overall survival (OS) of various types of cancers, including AGC (Kim and Oh, 2018).